Treatment of NDM-Producing Carbapenem-Resistant Klebsiella Urinary Tract Infection
For NDM-producing carbapenem-resistant Klebsiella urinary tract infections, use ceftazidime-avibactam combined with aztreonam as first-line therapy, with intravenous fosfomycin-containing combinations as an alternative when susceptibility is confirmed. 1
Primary Treatment Recommendation
The combination of ceftazidime-avibactam plus aztreonam is the preferred regimen for NDM-producing CRE infections, including urinary sources. This recommendation is based on moderate-certainty evidence showing significant mortality reduction (HR 0.37,95% CI 0.13-0.74) in patients with MBL-producing CRE bacteremia, with 82 of 102 patients having NDM-producing strains 1. The synergistic mechanism works because aztreonam remains stable against metallo-beta-lactamases while ceftazidime-avibactam protects aztreonam from other beta-lactamases.
Dosing Regimen
- Ceftazidime-avibactam: 2.5 g IV every 8 hours (adjust for renal dysfunction)
- Aztreonam: 2 g IV every 8 hours 2
- Consider 3-hour extended infusions for optimal pharmacodynamics 1
Recent clinical data from Poland demonstrated 100% microbiological eradication in 23 patients with KP-NDM infections (including urinary sources) treated with this combination, with only 17.4% mortality primarily attributable to underlying conditions rather than infection 2.
Alternative Treatment Options
Fosfomycin-Containing Combinations
Intravenous fosfomycin-containing combination therapy is recommended when the isolate is susceptible to fosfomycin or demonstrates synergistic activity (conditional recommendation, very low-quality evidence) 3. This option is particularly relevant given:
- Variable fosfomycin susceptibility rates in CRKP (39-99%) 3
- Demonstrated synergistic in-vitro activity against CRKP 3
- Clinical success in kidney transplant recipients with NDM-1 strains using prolonged combination therapy (imipenem/cilastatin + gentamicin/colistin for 21-27 days, followed by oral fosfomycin) 4
Critical contraindications: Avoid fosfomycin in patients with hypernatremia, cardiac insufficiency, or renal insufficiency 3.
Oral Fosfomycin for Uncomplicated Cystitis
For uncomplicated lower urinary tract infections only, oral fosfomycin trometamol may be considered, though susceptibility is limited (33.7% in recent data) 5. This represents a salvage option when parenteral therapy is not feasible, but should not be used for complicated UTI or pyelonephritis 6.
Treatment Duration and Monitoring
- Duration: 21-27 days for complicated UTI, followed by oral fosfomycin prophylaxis in select cases 4
- Therapeutic drug monitoring (TDM): Strongly recommended for aminoglycosides and polymyxins if used, especially in critically ill patients or those with renal dysfunction 3
- Microbiological confirmation: Always confirm NDM production and perform antimicrobial susceptibility testing before finalizing therapy 3
Common Pitfalls to Avoid
Do not use ceftazidime-avibactam monotherapy for NDM producers—it lacks activity against metallo-beta-lactamases and requires aztreonam for efficacy 1, 7
Do not rely on standard susceptibility testing alone for the ceftazidime-avibactam/aztreonam combination—no standardized methods or breakpoints exist yet 1
Avoid nitrofurantoin and ciprofloxacin—resistance rates are extremely high (92.3% and 100% respectively) 5
Do not use trimethoprim-sulfamethoxazole empirically—only 11.1% susceptibility overall, though recent data shows increasing susceptibility (24.1% post-2020) 5
Cefiderocol concerns: While potentially active against NDM producers, higher MICs are concerning and clinical experience is limited 7
When Preferred Options Are Unavailable
If ceftazidime-avibactam or aztreonam are unavailable:
- Aminoglycoside-containing combinations may improve cure rates and reduce mortality (conditional recommendation, very low-quality evidence), though nephrotoxicity risk requires careful monitoring 3
- Colistin-based combinations remain second-line options only when in vitro susceptibility is demonstrated with appropriate methods 7
- High-dose extended-infusion meropenem plus polymyxin shows low-certainty evidence for benefit when meropenem MIC ≤16 mg/L, though this is primarily studied in KPC producers 1
The aztreonam-avibactam combination (investigational) provides future hope for NDM producers but is not yet clinically available 7.